Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies

Abstract

Summary

What is this summary about?

● This is a plain language summary of two articles originally published in The New England Journal of Medicine and The Lancet Respiratory Medicine. These articles presented the results of GALATHEA and TERRANOVA, two clinical studies that took place across 41 countries.

○ GALATHEA and TERRANOVA measured how patients’ COPD changed from before their first benralizumab (10, 30, or 100 mg) injection, to after 56 weeks of treatment.

○ In both studies, benralizumab was compared with placebo.

○ To see whether benralizumab treatment would benefit any particular patients included in these studies, researchers carried out an additional analysis following the main studies of GALATHEA and TERRANOVA.

Keywords

benralizumab biologic chronic obstructive pulmonary disease eosinophil GALATHEA interleukin-5 TERRANOVA

Click here to view the PDF

Footnotes

Acknowledgements

The GALATHEA (NCT02138916) and TERRANOVA (NCT02155660) studies were sponsored by AstraZeneca. The authors would like to thank the clinical study participants and their family members and carers, as well as the investigators and staff at the study centers who cared for the participants in the clinical studies.